Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

B. Karaszewska · SciRah

Researcher profile · Semantic Scholar

B. Karaszewska

Share profile

B. Karaszewska — researcher profile on SciRah

h-index: 22
Works: 48
Citations: 8,846

Most-cited papers

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.
A. Hauschild, J. Grob, L. Demidov, T. Jouary +17 more
2012The Lancet2,856 citations
Semantic Scholar
Improved overall survival in melanoma with combined dabrafenib and trametinib.
C. Robert, B. Karaszewska, J. Schachter, P. Rutkowski +23 more
2015New England Journal of Medicine2,489 citations Open access
Semantic Scholar
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.
C. Robert, J. Grob, D. Stroyakovskiy, B. Karaszewska +22 more
2019New England Journal of Medicine1,166 citations Open access
Semantic Scholar
Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial
D. Catenacci, N. Tebbutt, I. Davidenko, A. Murad +17 more
2017The Lancet Oncology312 citations Open access
Semantic Scholar
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study
G. de Castro, I. Kudaba, Yi-Long Wu, G. Lopes +14 more
2022Journal of Clinical Oncology257 citations Open access
Semantic Scholar
Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
J. Grob, M. Amonkar, B. Karaszewska, J. Schachter +21 more
2015The Lancet Oncology234 citations Open access
Semantic Scholar
CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
X. Pivot, A. Manikhas, B. Żurawski, E. Chmielowska +17 more
2015Journal of Clinical Oncology224 citations Open access
Semantic Scholar
Atezolizumab with enzalutamide vs enzalutamide alone in metastatic castration-resistant prostate cancer: a randomised phase 3 trial
T. Powles, Kobe Yuen, S. Gillessen, E. Kadel +16 more
2022Nature Medicine218 citations Open access
Semantic Scholar
Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials.
D. Schadendorf, G. Long, D. Stroiakovski, B. Karaszewska +22 more
2017European Journal of Cancer169 citations
Semantic Scholar
Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study.
D. Cunningham, N. Tebbutt, I. Davidenko, A. Murad +15 more
2015141 citations
Semantic Scholar
An update on BREAK-3, a phase III, randomized trial: Dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM).
A. Hauschild, J. Grob, L. Demidov, T. Jouary +16 more
2013118 citations
Semantic Scholar
Randomized Open-Label Controlled Study of Cancer Vaccine OSE2101 Versus Chemotherapy in HLA-A2-positive Patients with Advanced Non-Small Cell Lung Cancer with Resistance to Immunotherapy: ATALANTE-1.
B. Besse, E. Felip, R. Campelo, M. Cobo +64 more
2023Annals of Oncology76 citations Open access
Semantic Scholar
Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib (D) + trametinib (T) in patients (pts) with unresectable or metastatic BRAF V600E/K–mutant cutaneous melanoma
C. Robert, B. Karaszewska, J. Schachter, P. Rutkowski +14 more
201672 citations Open access
Semantic Scholar
A Multicenter Phase II Study of AMG 337 in Patients with MET-Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma and Other MET-Amplified Solid Tumors
E. Van Cutsem, B. Karaszewska, Yoon-Koo Kang, H. Chung +6 more
2018Clinical Cancer Research65 citations Open access
Semantic Scholar
Eltrombopag for thrombocytopenia in patients with advanced solid tumors receiving gemcitabine-based chemotherapy: a randomized, placebo-controlled phase 2 study
Eric S. Winer, H. Safran, B. Karaszewska, S. Bauer +6 more
2017International journal of hematology62 citations
Semantic Scholar
Eltrombopag with gemcitabine-based chemotherapy in patients with advanced solid tumors: a randomized phase I study
E. Winer, H. Safran, B. Karaszewska, D. Richards +8 more
2014Cancer Medicine52 citations Open access
Semantic Scholar
Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine.
J. Grob, M. Amonkar, S. Martı́n-Algarra, L. Demidov +13 more
2014Annals of Oncology52 citations Open access
Semantic Scholar
1092PDAN UPDATE ON OVERALL SURVIVAL (OS) AND FOLLOW-ON THERAPIES IN BREAK-3, A PHASE III, RANDOMIZED TRIAL: DABRAFENIB (D) VS. DACARBAZINE (DTIC) IN PATIENTS (PTS) WITH BRAF V600E MUTATION-POSITIVE METASTATIC MELANOMA (MM).
A. Hauschild, J. Grobb, L. Demidov, T. Jouary +15 more
2014Annals of Oncology40 citations Open access
Semantic Scholar
Final analysis of the phase III KEYNOTE-042 study: Pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy for patients (Pts) with PD-L1-positive locally advanced/metastatic NSCLC.
T. Mok, Y.-L. Wu, I. Kudaba, D. Kowalski +13 more
2019Annals of Oncology38 citations Open access
Semantic Scholar
FP13.04 KEYNOTE-042 3-Year Survival Update: 1L Pembrolizumab vs Platinum-Based Chemotherapy for PD-L1+ Locally Advanced/Metastatic NSCLC
B. Cho, Y.-L. Wu, G. Lopes, I. Kudaba +14 more
202126 citations Open access
Semantic Scholar
A phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancer
W. Janni, T. Sarosiek, B. Karaszewska, J. Pikiel +9 more
2014Breast Cancer Research and Treatment25 citations Open access
Semantic Scholar
Chemotherapy-induced peripheral neuropathy - diagnosis, evolution and treatment.
D. Iżycki, A. Niezgoda, M. Kaźmierczak, T. Piorunek +3 more
2016Ginekologia Polska24 citations Open access
Semantic Scholar
Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study
S. Kuemmel, C. Tondini, J. Abraham, Z. Nowecki +12 more
2021Breast Cancer Research and Treatment22 citations Open access
Semantic Scholar
Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib
J. C. Brase, Robert F. H. Walter, A. Savchenko, D. Gusenleitner +21 more
2021Clinical Cancer Research21 citations Open access
Semantic Scholar
LBA4_PRCOMBI-V: A RANDOMISED, OPEN-LABEL, PHASE III STUDY COMPARING THE COMBINATION OF DABRAFENIB (D) AND TRAMETINIB (T) WITH VEMURAFENIB (V) AS FIRST-LINE THERAPY IN PATIENTS (PTS) WITH UNRESECTABLE OR METASTATIC BRAF V600E/K MUTATION-POSITIVE CUTANEOUS MELANOMA
C. Robert, B. Karaszewska, J. Schachter, P. Rutkowski +16 more
201415 citations Open access
Semantic Scholar
Final overall survival analysis of a phase II trial evaluating vinorelbine and lapatinib in women with ErbB2 overexpressing metastatic breast cancer.
W. Janni, T. Sarosiek, B. Karaszewska, J. Pikiel +10 more
2015Breast12 citations Open access
Semantic Scholar
363 KEYNOTE-042 5-year survival update: pembrolizumab versus chemotherapy in patients with previously untreated, PD-L1–positive, locally advanced or metastatic non–small-cell lung cancer
G. de Castro, I. Kudaba, Yi-Long Wu, G. Lopes +14 more
2021Journal for ImmunoTherapy of Cancer11 citations Open access
Semantic Scholar
Brain metastasis as the first symptom of gastric cancer--case report and literature review.
D. Murawa, P. Nowaczyk, M. Szymkowiak, B. Karaszewska
2013Polski przeglad chirurgiczny9 citations
Semantic Scholar
Hauschild A, Grob JJ, Demidov LV et al.Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380:358-365
A. Hauschild, J. Grob, L. Demidov, T. Jouary +17 more
20128 citations
Semantic Scholar
Five-year analysis on the long-term effects of dabrafenib plus trametinib (D + T) in patients with BRAF V600–mutant unresectable or metastatic melanoma.
P. Nathan, C. Robert, J. Grob, D. Stroyakovskiy +15 more
2019Journal of Clinical Oncology7 citations
Semantic Scholar
Safety and efficacy of eltrombopag (epag) versus placebo (pbo) for the treatment (tx) of chemotherapy-induced thrombocytopenia (CIT) in patients with solid tumors receiving gemcitabine (gem)-based chemotherapy (ctx): A phase I study.
E. Winer, H. Safran, B. Karaszewska, D. Richards +8 more
20126 citations
Semantic Scholar
A phase II randomized trial of lapatinib with either vinorelbine or capecitabine as first- and second-line therapy for HER2 overexpressing metastatic breast cancer (MBC).
C. Papadimitriou, T. Sarosiek, J. Pikiel, B. Karaszewska +8 more
20116 citations
Semantic Scholar
Subcutaneous trastuzumab (H SC) with intravenous pertuzumab (P IV) and docetaxel (D IV) in HER2-positive advanced breast cancer (BC): MetaPHER second interim analysis.
S. Kümmel, C. Tondini, J. Abraham, Z. Nowecki +12 more
2018Annals of Oncology4 citations Open access
Semantic Scholar
Dose distribution transfer from CyberKnife to Varian treatment planning system
W. Osewski, K. Ślosarek, B. Karaszewska
20143 citations Open access
Semantic Scholar
Abstract PD1-04: Results of a phase II double-blinded, randomized, placebo-controlled clinical trial of Indoximod, an Indoleamine-2,3-dioxygenase 1 (IDO1) inhibitor, in combination with Taxane chemotherapy in metastatic breast cancer (MBC)
V. Mariotti, Shou-Ching Tang, P. Dillon, A. Montero +17 more
2020Poster Spotlight Session Abstracts2 citations
Semantic Scholar
Safety and efficacy of eltrombopag (EPAG) vs placebo (PBO) for treatment of chemotherapy (CTx)-induced thrombocytopenia (TCP) in patients (Pts) with solid tumors receiving gemcitabine (GEM)-based CTx: A phase 2 study.
E. Winer, H. Safran, F. Forget, B. Karaszewska +7 more
20152 citations
Semantic Scholar
Abstract P5-18-21: A Phase II randomized trial of lapatinib with either vinorelbine or capecitabine as first- and second-line therapy for ErbB2-overexpressing metastatic breast cancer (MBC)
W. Janni, T. Sarosiek, J. Pikiel, B. Karaszewska +9 more
20122 citations
Semantic Scholar
A phase II randomized trial of lapatinib with either vinorelbine or capecitabine in ErbB2-overexpressing first- and second-line metastatic breast cancer (MBC).
W. Janni, J. Alvarez, C. Papadimitriou, B. Karaszewska +3 more
20102 citations
Semantic Scholar
Abstract P1-18-05: Subcutaneous trastuzumab and hyaluronidase-oysk with intravenous pertuzumab and docetaxel in HER2-positive advanced breast cancer: Final analysis of the phase IIIb, multicenter, open-label, single-arm MetaPHER study
S. Kümmel, C. Tondini, J. Abraham, Z. Nowecki +13 more
20201 citations
Semantic Scholar
Characteristics of Patients With a Complete Response Treated With Dabrafenib + Trametinib Combination Therapy: Findings From Pooled COMBI-d and COMBI-v 5-Year Analysis
C. Robert, J. Grob, D. Stroyakovskiy, B. Karaszewska +15 more
20201 citations Open access
Semantic Scholar
A randomized, open label, phase II study of prophylactic octreotide (OCT) to prevent/reduce the frequency and severity of diarrhea in patients (pts) receiving lapatinib (LAP) with capecitabine (CAP) for the treatment of metastatic breast cancer (mBC).
P. Krivorotko, B. Karaszewska, S. Chan, M. Wieczorek-Rutkowska +7 more
2018Annals of Oncology1 citations Open access
Semantic Scholar
1092PD AN UPDATE ON OVERALL SURVIVAL (OS) AND FOLLOW-ON
A. Hauschild, J. Grobb, L. Demidov, T. Jouary +18 more
20141 citations
Semantic Scholar
Abstract LB331: First-line (1L) trastuzumab deruxtecan (T-DXd) + rilvegostomig (rilve) + fluoropyrimidine (FP) in HER2-positive (HER2+) gastric cancer (GC), gastroesophageal junction adenocarcinoma (GEJA), or esophageal adenocarcinoma (EA): DESTINY-Gastric03 (DG-03) Part 4 arm A results
Y. Janjigian, H. V. van Laarhoven, H. Shoji, L. Wyrwicz +15 more
2026Cancer Research0 citations
Semantic Scholar
First-line (1L) trastuzumab deruxtecan (T-DXd)–based regimens in advanced HER2-expressing gastric cancer (GC), gastroesophageal junction adenocarcinoma (GEJA), or esophageal adenocarcinoma (EA): Safety results from DESTINY-Gastric03 (DG-03) Part 2 arms D and F, and Part 4.
Y. Janjigian, H. Shoji, Anna Kowalczyk, S. Rha +16 more
2026Journal of Clinical Oncology0 citations
Semantic Scholar
Subcutaneous Trastuzumab with Pertuzumab and Docetaxel in HER2-Positive Metastatic Breast Cancer: Final Analysis of MetaPHER, A Phase 3b Single-Arm Safety Study
S. Kuemmel, C. Tondini, J. Abraham, Z. Nowecki +12 more
20200 citations Open access
Semantic Scholar
Długotrwała odpowiedź na leczenie chemioterapią metronomiczną doustną winorelbiną u 46-letniej pacjentki z rozpoznaniem raka piersi w stadium rozsiewu
Piotr Witasik, B. Karaszewska
20190 citations
Semantic Scholar
3345 COMBI-v: health-related quality of life (HRQoL) impact of the combination of dabrafenib and trametinib (D+T) vs vemurafenib (V) in patients with BRAF V600 metastatic melanoma (MM)
J. Grob, M. Amonkar, B. Karaszewska, J. Schachter +16 more
20150 citations
Semantic Scholar
OT1-02-09: A Phase II Randomized Trial of Lapatinib with Either Vinorelbine or Capecitabine as First- and Second-Line Therapy for HER2−Overexpressing Metastatic Breast Cancer.
W. Janni, J. Pikiel, T. Sarosiek, B. Karaszewska +9 more
20110 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

A. Hauschild×15
Invite
A. Hauschild — researcher profile on SciRah
J. Schachter×10
Invite
J. Schachter — researcher profile on SciRah
P. Rutkowski×10
Invite
P. Rutkowski — researcher profile on SciRah
J. Grob×9
Invite
J. Grob — researcher profile on SciRah

V. Chiarion-Sileni

×9

Invite

V. Chiarion-Sileni — researcher profile on SciRah

D. Schadendorf×9

Invite

D. Schadendorf — researcher profile on SciRah

Invite

G. Long — researcher profile on SciRah

I. Bondarenko×8

Invite

I. Bondarenko — researcher profile on SciRah

Invite

C. Caglevic — researcher profile on SciRah

Invite

C. Robert — researcher profile on SciRah

A. Mackiewicz×7

Invite

A. Mackiewicz — researcher profile on SciRah

Invite

K. Flaherty — researcher profile on SciRah